Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemiaSTAM, Ronald W; DEN BOER, Monique L; ARMSTRONG, Scott A et al.Blood. 2005, Vol 106, Num 7, pp 2484-2490, issn 0006-4971, 7 p.Article

Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V K1T mutationGOTLIB, Jason; BERUBE, Caroline; LICHY, Jack H et al.Blood. 2005, Vol 106, Num 8, pp 2865-2870, issn 0006-4971, 6 p.Article

Le PKC 412 = PKC 412LANSIAUX, A; FABBRO, D; MEYER, T et al.Bulletin du cancer. 1999, Vol 86, Num 7-8, pp 614-617, issn 0007-4551Article

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412STONE, Richard M; DEANGELO, Daniel J; FOX, Edward A et al.Blood. 2005, Vol 105, Num 1, pp 54-60, issn 0006-4971, 7 p.Article

Plasma inhibitory activity (PIA) : a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitorsLEVIS, Mark; BROWN, Patrick; KANTARJIAN, Hagop et al.Blood. 2006, Vol 108, Num 10, pp 3477-3483, issn 0006-4971, 7 p.Article

Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412GROWNEY, Joseph D; CLARK, Jennifer J; ADELSPERGER, Jennifer et al.Blood. 2005, Vol 106, Num 2, pp 721-724, issn 0006-4971, 4 p.Article

The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts : the induction of cytotoxicity varies with dependence on FLT3 signaling in both flt3-mutated and wild-type casesKNAPPER, Steven; MILLS, Kenneth I; GILKES, Amanda F et al.Blood. 2006, Vol 108, Num 10, pp 3494-3503, issn 0006-4971, 10 p.Article

The phosphatidylinositide 3'-kinase/akt survival pathway is a target for the anticancer and radiosensitizing agent PKC412, an inhibitor of protein kinase CTENZER, Angela; ZINGG, Daniel; ROCHA, Sonia et al.Cancer research (Baltimore). 2001, Vol 61, Num 22, pp 8203-8210, issn 0008-5472Article

PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the d816v-mutated variant of KIT : comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effectsGLEIXNER, Karoline V; MAYERHOFER, Matthias; PICKL, Winfried F et al.Blood. 2006, Vol 107, Num 2, pp 752-759, issn 0006-4971, 8 p.Article

Differential p53-dependent mechanism of radiosensitization in vitro and in vivo by the protein kinase C-specific inhibitor PKC412ZAUGG, Kathrin; ROCHA, Sonia; RESCH, Hildegard et al.Cancer research (Baltimore). 2001, Vol 61, Num 2, pp 732-738, issn 0008-5472Article

PKC412-a protein kinase inhibitor with a broad therapeutic potential : Protein kinaseFABBRO, D; RUETZ, S; BODIS, S et al.Anti-cancer drug design. 2000, Vol 15, Num 1, pp 17-28, issn 0266-9536Article